دورية أكاديمية
أعرض في EDS

Association of race and ethnicity with clinical phenotype, genetics, and survival in pediatric acute myeloid leukemia.

التفاصيل البيبلوغرافية
العنوان: Association of race and ethnicity with clinical phenotype, genetics, and survival in pediatric acute myeloid leukemia.
المؤلفون: Conneely SE; Department of Pediatrics, Baylor College of Medicine, Houston, TX., McAtee CL; Department of Pediatrics, Baylor College of Medicine, Houston, TX., Gupta R; Department of Pediatrics, Baylor College of Medicine, Houston, TX., Lubega J; Department of Pediatrics, Baylor College of Medicine, Houston, TX., Scheurer ME; Department of Pediatrics, Baylor College of Medicine, Houston, TX., Rau RE; Department of Pediatrics, Baylor College of Medicine, Houston, TX.
المصدر: Blood advances [Blood Adv] 2021 Dec 14; Vol. 5 (23), pp. 4992-5001.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Washington, DC : American Society of Hematology, [2016]-
مواضيع طبية MeSH: Ethnicity* , Leukemia, Myeloid, Acute*/diagnosis , Leukemia, Myeloid, Acute*/drug therapy , Leukemia, Myeloid, Acute*/genetics, Adolescent ; Hispanic or Latino/genetics ; Humans ; Phenotype ; Proportional Hazards Models
مستخلص: Black and Hispanic children with acute myeloid leukemia (AML) have worse outcomes compared with White children. AML is a heterogeneous disease with numerous genetic subtypes in which these disparities have not been specifically investigated. In this study, we used the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) database to examine the association of race-ethnicity with leukemia cytogenetics, clinical features, and survival outcomes within major cytogenetic subgroups of pediatric AML. Compared with White non-Hispanic patients, t(8;21) AML was more prevalent among Black (odds ratio [OR], 2.22; 95% confidence interval [CI], 1.28-3.74) and Hispanic patients (OR, 1.74; 95% CI, 1.05-2.83). The poor prognosis KMT2A rearrangement t(6;11)(q27;q23) was more prevalent among Black patients (OR, 6.12; 95% CI, 1.81-21.59). Among those with KMT2Ar AML, Black race was associated with inferior event-free survival (EFS) (hazard ratio [HR], 2.31; 95% CI, 1.41-3.79) and overall survival (OS) (HR, 2.54; 1.43-4.51). Hispanic patients with KMT2Ar AML also had inferior EFS (HR, 2.20; 95% CI, 1.27-3.80) and OS (HR, 2.07; 95% CI, 1.09-3.93). Similarly, among patients with t(8;21) or inv(16) AML (ie, core-binding factor [CBF] AML), Black patients had inferior outcomes (EFS HR, 1.93; 95% CI, 1.14-3.28 and OS HR, 3.24; 95% CI, 1.60-6.57). This disparity was not detected among patients receiving gemtuzumab ozogamicin (GO). In conclusion, racial-ethnic disparities in survival outcomes among young people with AML are prominent and vary across cytogenetic subclasses. Future studies should explore the socioeconomic and biologic determinants of these disparities.
(© 2021 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
References: Blood Cancer J. 2019 May 21;9(6):51. (PMID: 31113932)
J Clin Oncol. 2014 Sep 20;32(27):3021-32. (PMID: 25092781)
Pediatr Blood Cancer. 2010 Oct;55(4):655-61. (PMID: 20533519)
Blood. 2008 Feb 1;111(3):1044-53. (PMID: 18000167)
Leuk Lymphoma. 2019 Sep;60(9):2190-2198. (PMID: 30732497)
Curr Hematol Malig Rep. 2019 Jun;14(3):179-186. (PMID: 31073772)
J Clin Oncol. 2016 Mar 1;34(7):747-55. (PMID: 26786921)
Pediatr Blood Cancer. 2007 Jan;48(1):10-5. (PMID: 16642489)
Cancer Discov. 2021 Mar;11(3):626-637. (PMID: 33277314)
PLoS Genet. 2012;8(3):e1002554. (PMID: 22412386)
Cancer. 2008 Nov 1;113(9):2575-96. (PMID: 18837040)
Am J Hematol. 2017 Feb;92(2):141-148. (PMID: 27862214)
Pediatr Hematol Oncol. 2018 Mar;35(2):95-110. (PMID: 29737912)
JAMA Netw Open. 2020 Apr 1;3(4):e202950. (PMID: 32267515)
Cancer. 2012 Feb 1;118(3):761-9. (PMID: 21766293)
J Clin Oncol. 2017 Aug 10;35(23):2674-2682. (PMID: 28644774)
Blood. 2006 Jul 1;108(1):74-80. (PMID: 16537811)
Pediatr Blood Cancer. 2017 Dec;64(12):. (PMID: 28727288)
Epidemiol Health. 2017 Aug 6;39:e2017035. (PMID: 29121709)
Pediatr Blood Cancer. 2019 Apr;66(4):e27583. (PMID: 30585685)
Epidemiology. 2011 Jul;22(4):582-5. (PMID: 21642779)
Pediatr Blood Cancer. 2017 Sep;64(9):. (PMID: 28266784)
J Clin Epidemiol. 2008 Apr;61(4):344-9. (PMID: 18313558)
JAMA Netw Open. 2020 Aug 3;3(8):e2016531. (PMID: 32816027)
J Clin Oncol. 2012 Jun 1;30(16):2005-12. (PMID: 22547602)
Nat Med. 2018 Jan;24(1):103-112. (PMID: 29227476)
Blood. 2009 Sep 17;114(12):2489-96. (PMID: 19528532)
Pediatr Res. 2020 Jan;87(2):227-234. (PMID: 31357209)
معلومات مُعتمدة: R01 CA183252 United States CA NCI NIH HHS
تواريخ الأحداث: Date Created: 20211007 Date Completed: 20220106 Latest Revision: 20220716
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC9153027
DOI: 10.1182/bloodadvances.2021004735
PMID: 34619758
قاعدة البيانات: MEDLINE
الوصف
تدمد:2473-9537
DOI:10.1182/bloodadvances.2021004735